Navigation Links
Hospira to Host Conference Call for First-Quarter 2009 Results
Date:3/30/2009

LAKE FOREST, Ill., March 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a leading global specialty pharmaceutical and medication delivery company, today announced that it will host a conference call to discuss its first-quarter 2009 results on Tuesday, April 28, 2009, at 8 a.m. Central time.

The company will release its first-quarter 2009 results earlier that morning, before the U.S. stock market open and the conference call.

A live webcast of the conference call will be available on Hospira's Web site at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the webcast. A replay will be available on the Hospira Web site for 30 days following the call.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has more than 14,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Hospira to Present at Cowen and Companys 29th Annual Health Care Conference March 17
2. Hospira Expands Board of Directors
3. Hospira Reports Fourth-Quarter and Full-Year 2008 Results
4. Hospiras Precedex(R) Phase IV Study Published in the Journal of the American Medical Association
5. Hospira to Host Conference Call for Fourth-Quarter 2008 Results and 2009 Projections
6. Hospira to Present at J.P. Morgans 27th Annual Healthcare Conference January 14
7. Hospira Names Ken Meyers to Lead Human Resources
8. Hospira Reports Third-Quarter 2008 Results
9. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
10. FDA Approves New Indication for Hospiras Precedex (Dexmedetomidine HCL) Injection
11. Hospira Announces New Contracts With Premier Purchasing Partners for Infusion Devices, Solutions And Equipment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... GoDaddy, IX Web Hosting and Bluehost are ... Server) hosting, which is the method of partitioning ... of which has the appearance and capabilities of ... recently compared many professional web hosting suppliers and ... VPS hosting suppliers in the global market. , ...
(Date:8/31/2014)... Mesa, Arizona (PRWEB) August 31, 2014 For ... ragweed is likely the culprit. Ragweed is the most common ... percent of Americans. , The most common symptoms of ragweed ... and throat, and sneezing. Ragweed allergy can also lead to ... ragweed allergies should consult an allergist about allergy immunotherapy - ...
(Date:8/31/2014)... 01, 2014 In order to celebrate the ... announced its latest designs and launched a big promotion. Now, ... , All the company’s new cars are made with ... for the global customers. As a matter of fact, it ... items. Those who are in need of cheap cars can ...
(Date:8/31/2014)... LabDoor.com tests the purity and label accuracy of ... website, “We buy products in the same fashion as ... sites. No manufacturer-supplied samples are permitted at LabDoor.” As ... a recent study was performed on twenty of the ... States for Vitamin D3 content, heavy metal contamination, and ...
(Date:8/31/2014)... 2014 In the wake of growing ... proposed legislation to require mandatory labeling of GMOs on ... purchasing decisions that affect their own health and the ... for stringent measures to eliminate GMOs from dietary supplements, ... Engagement” (I.C.E.) initiative with the objective of advancing the ...
Breaking Medicine News(10 mins):Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3
... , , ... Reportlinker.com announces that a new market research report is available ... Endoscopy Devices , , http://www.reportlinker.com/p0131252/Gastrointestinal-Endoscopy-Devices.html ... market for Gastrointestinal Endoscopy Devices in Millions of US$ analyzed by ...
... , Rx Bottles Filled with ... Fix Broken System Upon His Return to Washington ... Members of Congress have just returned to Washington D.C. after their ... to make reforming health care a top priority. With a giant ...
... Economic slump encourages more people ... Vancouver, ... more Canadians are making the decision to head back to school to re-train, instead of waiting ... Canada, has seen a dramatic spike in enrollments in 2009. Between July 2008 and July 2009, ...
... , , ... San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a ... National Institute of Allergy and Infectious Disease (National Institutes of Health) ... H5N1 Avian influenza. , , "We thank ...
... ECCO 15 ESMO 34 will take place at ... D-14055 Berlin, Germany ( www.icc-berlin.de ) from Sunday 20 ... be more than 2,000 presentations and over 15,000 participants ... congress to date. The congress will discuss the ...
... , ATLANTA, Sept. 8 Renowned ... Coke, in collaboration with the American Dietetic Association (ADA) are providing ... Tastefully campaign will feature pop-up kitchens in midtown Manhattan and Boston, ... are all a part of living well. , , ...
Cached Medicine News:Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 2Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 3Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 4Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 5Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 6Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 7Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 8Health News:Fall 2009 Sees Spike in Enrollments at CDI College 2Health News:Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine 2Health News:Media registration for ECCO 15 -- ESMO 34 multidisciplinary cancer congress 2Health News:Media registration for ECCO 15 -- ESMO 34 multidisciplinary cancer congress 3Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 2Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 3Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 4
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... 5, 2011 Today Scios Inc. announced an agreement with ... misbranding of NATRECOR® (nesiritide), a prescription medication for patients with ... Scios Inc. entered a guilty plea to a single misdemeanor ... to pay an $85 million fine. Scios acknowledges ...
... Puma Biotechnology, Inc., a development stage biopharmaceutical company, ... the worldwide commercial rights to neratinib, a potent, ... through the epidermal growth factor receptors, ErbB1 (EGFR), ... being studied in the neoadjuvant, adjuvant and metastatic ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5